[Basic and clinical studies on cefminox in the field of obstetrics and gynecology].
Human pharmacokinetics and clinical studies of cefminox (CMNX, MT-141) were carried out and the following results were obtained. The concentrations of CMNX transferred to the uterus and its appendages after CMNX 1 g intravenous injection were maintained above 12.5 micrograms/g during first 3 hours or more. The concentrations of CMNX transferred to the pelvic dead space exudate were above 12.5 micrograms/ml during 6 hours or more. Those concentrations were sufficiently effective against the major pathogens (Gram-negative and anaerobic bacteria) demonstrated in the field of obstetrics and gynecology. We administered CMNX to 4 cases with postoperative infections at a dose of 2 g per day (twice a day) for a period of 4-6 days. The clinical effect was excellent in 3, good in 1 case. No side effect was observed.
D000038:Abscess / Q000188:drug therapy; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism; D002513:Cephamycins / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D004927:Escherichia coli Infections / Q000188:drug therapy; D005122:Exudates and Transudates / Q000378:metabolism; D005260:Female; D006801:Humans; D007700:Kinetics; D008875:Middle Aged; D010249:Parametritis / Q000188:drug therapy; D014599:Uterus / Q000378:metabolism; D014621:Vagina / Q000378:metabolism
D002513:Cephamycins; C046079:cefminox